Desmond-Hellmann discusses the drug development process and shares her experience with the targeted cancer therapeutic, Herceptin.
|Download:||This Video Subtitled Videos: English|
|Trouble Viewing? Try it on iTunes.Report a problem.|
Research Papers Discussed in this Talk
Slamon, D.J. et al. (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. New England Journal of Medicine 344(11):783-792.
Stern, H.M. (2012) Improving treatment of HER2-positive cancers: opportunities and challenges. Science Translational Medicine 4(127):1-10.
Educator Resources (Educators only)
These questions and answers were designed to link the iBiology video to the research paper and for use as a classroom activity.
Prepared by Dr. Kirk Ehmsen.
About the Speaker
An oncologist and leader in biotechnology, Susan Desmond-Hellmann is currently Chancellor of the University of California San Francisco. Prior to joining UCSF, Desmond-Hellmann spent 14 years at Genentech where she served as President, Product Development from 2004-2009. Under her direction, Genentech became the nation's No. 1 producer of anti-cancer drug treatments.
- Brian Druker iBioSeminar: Imatinib (Gleevec): A Targeted Cancer Therapy
- Mark Tessier-Lavigne iBioMagazine: Careers in Biotechnology
- Wells and Akin iBioSeminar: Introduction to Drug Discovery